Download PDF
Viszeralchirurgie 2001; 36(4): 242-246
DOI: 10.1055/s-2001-16835
ORIGINALARBEIT
© Georg Thieme Verlag Stuttgart · New York

Stellenwert der Chemotherapie im Rahmen des Therapiekonzeptes bei Weichteilsarkomen

Significance of chemotherapy in the therapeutical concept of soft tissue sarcomasJ. Fahlke, H. Lippert
  • Klinik für Allgemein-, Viszeral- und Gefäßchirurgie, Otto-von-Guericke-Universität, Magdeburg
Further Information

Publication History

Publication Date:
29 August 2001 (online)

    Permissions and Reprints

Zusammenfassung.

Unter dem Begriff Weichteilsarkome wird eine relativ seltene Gruppe von Tumoren zusammengefasst. Trotz der Vielzahl verschiedener histologischer Subtypen ist ihr Ansprechen auf unterschiedliche Formen der Therapie sehr ähnlich. Der Stellenwert der neoadjuvanten, adjuvanten und palliativen Chemotherapie im multimodalen Therapiekonzept der Weichteilsarkome wird bewertet, wobei derzeit ein Einbringen der Patienten in Studien zu empfehlen ist. Die optimale Behandlung von Weichgewebssarkomen ist eine individuelle, auf den einzelnen Patienten zugeschnittene Therapie.

Significance of chemotherapy in the therapeutical concept of soft tissue sarcomas.

Soft-tissue sarcomas are a relatively rare disease. Various different histological subtypes exist that behave similarly regarding response to treatment. The status of neoadjuvant, adjuvant and palliative chemotherapy in the multi-modal therapy-concept of the soft part-sarcomas is assessed, at this time patients should be treated in studies. In general, optimal treatment of soft-tissue sarcoma requires individual care tailored to the single patient.

Schlüsselwörter:

Weichteilsarkome - Therapiekonzepte - Chemotherapie

Key words:

Soft-tissue sarcomas - Chemotherapy - Therapeutical concept

Literatur

  • 1 Bellmunt J, Eres N, Ribas A, Casado S, Albanell J, Baselga J. Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis.  Cancer Chemother Pharmacol. 1997;  40 273-276
    CrossrefPubMedGoogle Scholar
  • 2 Berry G, Billingham M, Torti F. Reduced cardiotoxicity in Aid's Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin as comared to doxorubicin. In preparation
  • 3 Bokemeyer C. New perspectives for the treatment of metastatic adult soft tissue sarcomas.  Forum Trends in experimental and clinical medicine. 1994;  4 331-345
    PubMedGoogle Scholar
  • 4 Bonadonna G, Gianni L, Santoro A, Bonfante V, Bidoli P, Casali P, Demichelli R, Valagussa P. Drugs ten years later: Epirubicin.  Ann Oncol. 1993;  4 359-369
    PubMedGoogle Scholar
  • 5 Casper E S, Gaynor J J, Harrison L B, Panicek D M, Hajdu S I, Brenna M F. Preoperative and postoperative adjuvant combination chemotherapy for adults with high grade soft tissue sarcoma.  Cancer. 1994;  73 1644-1651
    PubMedGoogle Scholar
  • 6 De Pas T, De Braud F, Comandone A, Masci G, Zampino G, Catanie C, Boni C, Gebbia V, Peruzzotti G, Goldhirsch A. A twelve days prolonged infusion of ifosfamid combined with full dose adriamycin in advanced soft tissue sarcomas. A phase I dose-escalation study.  Proceedings of ASCO Volume. 1999;  2092 542a
    PubMedGoogle Scholar
  • 7 Edmonson J R, Ryan L M, Blum R H, Brooks J S, Shiraki M, Freytak S, Parkinson D R. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin and cisplatin against advanced soft tissue sarcomas.  J Clin Oncol. 1993;  11 1269-1275
    CrossrefPubMedGoogle Scholar
  • 8 Elias A D, Eder J P, Shea T, Begg C B, Frei E, Antman K H. High dose ifosfamid with mesna uroprotection: A phase-I-study.  Clin Oncol. 1990;  8 170-178
    PubMedGoogle Scholar
  • 9 Enneking W. A system of staging musculoskeletal neoplasms.  Clin Orthop. 1986;  20 40
    PubMedGoogle Scholar
  • 10 Hoos A, Lewis J J, Brennan M F. Weichgewebssarkome - prognostische Faktoren und multimodale Therapie.  Chirurg. 2000;  71 787-794
    CrossrefPubMedGoogle Scholar
  • 11 Judson I, Radford J, Blay J-Y, Van Hoesel Q, Le Cesne A, van Oosterom A, Nielsen O S, Kamby C, Woll P, Harris M, Hermans C, Donato di Paoloa E, Verweij J. A randomised phase II trial of Caelyx®/Doxil® versus doxorubicin in advanced or metastatic soft tissue sarcomas - An EORTC soft tissue and bone sarcoma group trial.  Proceedings of ASCO Volume. 1999;  2089 541a
    PubMedGoogle Scholar
  • 12 Lopez-Pousa A, Buesa M, Montalar J, Martin J, Maurel J, del Muro J G, De Las Penas R, Cruz J, Cassinello J, Sevilla I, Balana C, Casado A, Bover I, Paredes A, Carles J, Poveda A. Phase II trial of doxorubicin and high-dose ifofsamid in advanced previously untreated soft tissue sarcoma patients. A study of the Spanish Group for Research on sarcomas.  Proceedings of ASCO Volume. 1999;  2101 544a
    PubMedGoogle Scholar
  • 13 Mansi J L, Fisher C, Wittshaw E, MacMillans S, King M, Stuart-Harris R. A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcomas.  Eur J Cancer Clin Oncol. 1988;  24 1439-1443
    CrossrefPubMedGoogle Scholar
  • 14 Martin F J, Gabizon A. Human pharmacokinetics of stealth liposomes containing doxorubicin.  J Cell Biochem. 1992;  16E 198
    PubMedGoogle Scholar
  • 15 North D. Pharmacokinetics, tumor localization and safety of Doxil in Aids patients with Kaposi's sarcoma.  Proceedings from the ASCO Volume. 1993;  12 51
    PubMedGoogle Scholar
  • 16 Papahadjopoulos D, Allan T M, Gabizon A, Mayhew E, Matthay K, Huang S K, Lee K D, Woodle M C, Lasic D D, Redemann C, et al. Sterically stabilized liposomes; improvement in pharmacokinetics and anti-tumor therapeutic efficacy.  PNAS. 1991;  88 11460-11464
    PubMedGoogle Scholar
  • 17 Patel S R, Vadhau-Raj S, Papadopolous N, Plager C, Burgess M A, Hays C, Benjamin R S. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies - dose-response and schedule dependence.  J Clin Oncol. 1997;  15 2378-2384
    CrossrefPubMedGoogle Scholar
  • 18 Peh W CG, Shek T WH, Wang S C, Wong J WK, Chien E P. Osteogenetic sarcoma with skeletal muscle metastases.  Skeletal Radiol. 1999;  28 298
    CrossrefPubMedGoogle Scholar
  • 19 Schlag P M, Tunn P U, Kettelhack C. Diagnostisches und therapeutisches Vorgehen bei Weichgewebstumoren.  Chirurg. 1997;  68 1309
    CrossrefPubMedGoogle Scholar
  • 20 Schmidt-Matthiessen A, Hovy L, Encke A. Weichgewebssarkome im Erwachsenenalter.  Zentralbl Chir. 1992;  117 374
    PubMedGoogle Scholar
  • 21 Schutte J, Mouridsen H T, Steward W, Santoro A, van Oosterom A T, Somers R, Blackledge G, Verweij J, Dembernowsky P, Thomas D, et al. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma.  Cancer Chemother Pharmacol. 1993;  31 (2) 204-209
    PubMedGoogle Scholar
  • 22 Skubitz M. A phase II trial of pegylated liposomal doxorubicin demonstrates activity in refractory sarcoma, mesothelioma and head and neck cancer.  Proceedings of ASCO Volume. 1999;  2090 541a
    PubMedGoogle Scholar
  • 23 Steward W P, Verweij J, Somers R, Spooner D, Kerbrat P, Clavel M, Crowther D, Rouesse J, Tursz T, Tueni E, et al. Granocyte-macrophage colony stimulating factor allows safe escalating of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.  J Clin Oncol. 1993;  11 15-21
    PubMedGoogle Scholar
  • 24 Sutton G, Blessing J A, Park R, Disaia P J, Rosenhein N. Ifosfamid treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group.  Obstet Gynecol. 1996;  87 747-750
    CrossrefPubMedGoogle Scholar
  • 25 Toma S, Tucci A, Villani G, Carteni G, Palumbo R. Liposomal doxorubicin in advanced pretreated soft tissue sarcomas: a phase II trial of the italian sarcoma group.  Proceedings of ASCO Volume. 1999;  2087 540a
    PubMedGoogle Scholar
  • 26 Weh H J, Agarwal K, Zornig, Schwarz R, Dietel M, Hossfeld D R. Treatment results obtained in metastatic soft-tissue sarcoma with a combination of doxorubicin and dacarbazine or doxorubicin and ifosfamide.  Cancer Chemother Pharmacol. 1993;  31 (2) 189-193
    PubMedGoogle Scholar
  • 27 Whiltshaw E, Westbury G, Harmer C, McKinna A, Fisher C. Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma.  Cancer Chemother Pharmacol. 1986;  18 (2) 10-12
    CrossrefPubMedGoogle Scholar

Dr. med. J. Fahlke

Klinik für Allgemein-, Viszeral- und Gefäßchirurgie
Otto-von-Guericke-Universität

Leipziger Straße 44
39112 Magdeburg